Latest Market Disclosure News

Monash IVF Group has affirmed its compliance with ASX continuous disclosure rules following a clinical incident involving an embryo transfer error at its Clayton laboratory. The company clarified the materiality and timing of its disclosures in response to ASX inquiries.

Patronus Resources has clarified that its recent share price jump stems from a third-party research report rather than undisclosed company news, following an ASX inquiry. The company also confirmed the recent release of exploration results from its Western Australian gold projects.

Black Canyon Limited has clarified that its recent share price and volume spike is linked to the upcoming second phase of drilling at its Wandanya manganese project, with no undisclosed information influencing trading.

OFX Group Limited has responded to ASX concerns over its FY25 earnings disclosure, confirming earnings below consensus but no breach of continuous disclosure rules.

Mithril Silver and Gold has acknowledged undisclosed channel sample results at its El Apomal target, explaining recent unusual trading activity. The company has entered a trading halt ahead of a formal announcement expected by 3 June 2025.

Axel REE Limited has responded to ASX Compliance queries confirming the timely disclosure of its latest rare earth element drilling results at the Poços de Caldas Caldera, emphasizing the incremental nature of the findings and ongoing compliance with listing rules.

Nufarm Limited confirms its half-year earnings align closely with analyst expectations despite a late-stage $16 million inventory valuation adjustment. The company maintains compliance with ASX disclosure rules amid market scrutiny.

Mayne Pharma has clarified why it did not disclose an FDA Untitled Letter to the market despite sharing it with its scheme bidder, reaffirming compliance with ASX rules amid recent share price volatility.

Alvo Minerals has voluntarily suspended trading of its shares on the ASX as it finalizes an Entitlement Offer and prepares to announce progress on the Lavra Velha Project acquisition.

Heavy Minerals Limited attributes its recent share price jump to media coverage about its upcoming Port Gregory Pre-Feasibility Study and confirms compliance with ASX disclosure rules.

Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.

Insignia Financial updates the market on its acquisition talks, revealing Bain Capital's withdrawal due to global market volatility while discussions with CC Capital continue without certainty.